Hymecromone Efficacy in the Treatment of Biliary Pancreatitis

Aim. To study the contribution of biliary sludge (BS) to the development of chronic pancreatitis in patients with gallbladder sludge and verified chronic pancreatitis; to evaluate the clinical efficacy and safety of hymecromone therapy according to clinical and laboratory signs, as well as dynamics...

Full description

Saved in:
Bibliographic Details
Main Authors: A. V. Okhlobystin, M. A. Tatarkina, O. Z. Okhlobystina, S. A. Budzinskiy, P. V. Pavlov, L. A. Labut
Format: Article
Language:Russian
Published: Gastro LLC 2019-12-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
Online Access:https://www.gastro-j.ru/jour/article/view/418
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823860160517373952
author A. V. Okhlobystin
M. A. Tatarkina
O. Z. Okhlobystina
S. A. Budzinskiy
P. V. Pavlov
L. A. Labut
author_facet A. V. Okhlobystin
M. A. Tatarkina
O. Z. Okhlobystina
S. A. Budzinskiy
P. V. Pavlov
L. A. Labut
author_sort A. V. Okhlobystin
collection DOAJ
description Aim. To study the contribution of biliary sludge (BS) to the development of chronic pancreatitis in patients with gallbladder sludge and verified chronic pancreatitis; to evaluate the clinical efficacy and safety of hymecromone therapy according to clinical and laboratory signs, as well as dynamics of gallbladder size and contractility.Materials and methods. An open single-centre clinical trial included 30 patients with chronic pancreatitis (CP), which was diagnosed according to the Cambridge criteria. All patients received hymocromone (Odeston®) 400 mg tid for 3 weeks. An analysis of the efficacy and safety of the studied drug was performed on the 21st day of treatment based on the results of laboratory tests, abdominal ultrasound, cholecystography and endosonography of the pancreatobiliary zone, quality-of-life assessment according to the SF-36 questionnaire, the frequency and severity of adverse effects (AE).Results. CP signs were found in 6.3 % of patients with gallbladder BS. CP was significantly more frequent in patients with putty-like bile (33.3 %, χ2 = 38.21, p < 0.00001). The area of the major duodenal papilla (MDP) was below normal in 78% of patients. According to factor analysis, monotherapy with hymocromone resulted in a decrease in abdominal pain, nausea, heaviness in the abdomen and bloating. By the end of the therapy, the quality of life according to the “BP” bodily pain scale of the SF-36 questionnaire significantly increased.Conclusions. Biliary sludge (including undiagnosed forms during routine examination) was found to be a factor in the development of CP. The medical correction of biliary disorders in CP should include selective antispasmodics. Hymecromone therapy demonstrates a good level of tolerability and safety, normalizes the motor function of the biliary tract and sphincter tone over a short period of time, and relieves CP symptoms.
format Article
id doaj-art-d131db32b5de4256ab6cce350b960984
institution Kabale University
issn 1382-4376
2658-6673
language Russian
publishDate 2019-12-01
publisher Gastro LLC
record_format Article
series Российский журнал гастроэнтерологии, гепатологии, колопроктологии
spelling doaj-art-d131db32b5de4256ab6cce350b9609842025-02-10T16:14:35ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732019-12-01295263510.22416/1382-4376-2019-29-5-26-35326Hymecromone Efficacy in the Treatment of Biliary PancreatitisA. V. Okhlobystin0M. A. Tatarkina1O. Z. Okhlobystina2S. A. Budzinskiy3P. V. Pavlov4L. A. Labut5I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)The Russian National Research Medical University named after N.I. PirogovI.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)Aim. To study the contribution of biliary sludge (BS) to the development of chronic pancreatitis in patients with gallbladder sludge and verified chronic pancreatitis; to evaluate the clinical efficacy and safety of hymecromone therapy according to clinical and laboratory signs, as well as dynamics of gallbladder size and contractility.Materials and methods. An open single-centre clinical trial included 30 patients with chronic pancreatitis (CP), which was diagnosed according to the Cambridge criteria. All patients received hymocromone (Odeston®) 400 mg tid for 3 weeks. An analysis of the efficacy and safety of the studied drug was performed on the 21st day of treatment based on the results of laboratory tests, abdominal ultrasound, cholecystography and endosonography of the pancreatobiliary zone, quality-of-life assessment according to the SF-36 questionnaire, the frequency and severity of adverse effects (AE).Results. CP signs were found in 6.3 % of patients with gallbladder BS. CP was significantly more frequent in patients with putty-like bile (33.3 %, χ2 = 38.21, p < 0.00001). The area of the major duodenal papilla (MDP) was below normal in 78% of patients. According to factor analysis, monotherapy with hymocromone resulted in a decrease in abdominal pain, nausea, heaviness in the abdomen and bloating. By the end of the therapy, the quality of life according to the “BP” bodily pain scale of the SF-36 questionnaire significantly increased.Conclusions. Biliary sludge (including undiagnosed forms during routine examination) was found to be a factor in the development of CP. The medical correction of biliary disorders in CP should include selective antispasmodics. Hymecromone therapy demonstrates a good level of tolerability and safety, normalizes the motor function of the biliary tract and sphincter tone over a short period of time, and relieves CP symptoms.https://www.gastro-j.ru/jour/article/view/418biliary pancreatitisbiliary sludgehymocromonetransabdominal ultrasound
spellingShingle A. V. Okhlobystin
M. A. Tatarkina
O. Z. Okhlobystina
S. A. Budzinskiy
P. V. Pavlov
L. A. Labut
Hymecromone Efficacy in the Treatment of Biliary Pancreatitis
Российский журнал гастроэнтерологии, гепатологии, колопроктологии
biliary pancreatitis
biliary sludge
hymocromone
transabdominal ultrasound
title Hymecromone Efficacy in the Treatment of Biliary Pancreatitis
title_full Hymecromone Efficacy in the Treatment of Biliary Pancreatitis
title_fullStr Hymecromone Efficacy in the Treatment of Biliary Pancreatitis
title_full_unstemmed Hymecromone Efficacy in the Treatment of Biliary Pancreatitis
title_short Hymecromone Efficacy in the Treatment of Biliary Pancreatitis
title_sort hymecromone efficacy in the treatment of biliary pancreatitis
topic biliary pancreatitis
biliary sludge
hymocromone
transabdominal ultrasound
url https://www.gastro-j.ru/jour/article/view/418
work_keys_str_mv AT avokhlobystin hymecromoneefficacyinthetreatmentofbiliarypancreatitis
AT matatarkina hymecromoneefficacyinthetreatmentofbiliarypancreatitis
AT ozokhlobystina hymecromoneefficacyinthetreatmentofbiliarypancreatitis
AT sabudzinskiy hymecromoneefficacyinthetreatmentofbiliarypancreatitis
AT pvpavlov hymecromoneefficacyinthetreatmentofbiliarypancreatitis
AT lalabut hymecromoneefficacyinthetreatmentofbiliarypancreatitis